Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q3 2023 · 10-Q
Revenue$3.53B$3.53B+11.3% vs Q3 2022 Net Income$504.00M$504.00M+168.1% vs Q3 2022 EPS Diluted$0.34$0.34+183.3% vs Q3 2022 Gross Profit$2,426,000,000+10.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$698,000,000+48.5% Free Cash Flowderived$508,000,000+58.8% Margins · derivedGross margin68.8%−0.3 pt vs Q3 2022
Operating margin19.6%+8.4 pt vs Q3 2022
Net margin14.3%+8.4 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 1, 2023 · 32 d after period end